This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Trulieve Cannabis (TRUL) Hisse Özeti
Trulieve Cannabis Corp. bir kenevir perakendecisi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
TRUL Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trulieve Cannabis Corp. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | CA$16.14 |
| 52 Haftanın En Yüksek Seviyesi | CA$18.50 |
| 52 Haftanın En Düşük Seviyesi | CA$4.45 |
| Beta | 1.86 |
| 1 Aylık Değişim | 46.06% |
| 3 Aylık Değişim | 83.83% |
| 1 Yıllık Değişim | 215.85% |
| 3 Yıllık Değişim | 202.81% |
| 5 Yıllık Değişim | -63.40% |
| Halka arzdan bu yana değişim | 61.72% |
Son Haberler & Güncellemeler
Recent updates
Anlatı Güncellemesi • May 30
TRUL: Schedule III Reclassification Pathway Will Drive Future Multiple Re Rating
Narrative Update on Trulieve Cannabis Analysts have raised their price target on Trulieve Cannabis by CA$8, reflecting updated assumptions for fair value, revenue growth, profit margins, and future P/E following recent sector research and regulatory commentary on cannabis rescheduling. Analyst Commentary Street research around Trulieve Cannabis has centered on how potential cannabis rescheduling could affect valuation, tax burdens, and long term earnings power.Anlatı Güncellemesi • Apr 23
TRUL: Schedule III Shift And Repriced P E Multiple Will Drive Upside
Analysts raised their price target for Trulieve Cannabis to CA$15.26 from CA$14.95, citing updated assumptions based on higher modeled revenue growth, stronger profit margins, and a more moderate future P/E multiple. Analyst Commentary Street research on the broader equity market has included several cautious revisions and lower price targets, which can help frame how bearish analysts might approach a stock like Trulieve Cannabis.
Anlatı Güncellemesi • Apr 08
TRUL: Higher Margin Profile And Rich Future P/E May Support Repricing
Analysts have lifted their fair value estimate for Trulieve Cannabis to CA$20.36 from CA$19.53, citing updated assumptions that reflect more conservative revenue growth, a higher profit margin profile, and a very large future P/E multiple that aligns with recent Street research patterns of recalibrating price targets while keeping core views intact. Analyst Commentary Street research across sectors shows a pattern of price target resets that keep long term theses largely intact, and this context helps frame how to read the updated fair value for Trulieve Cannabis.Anlatı Güncellemesi • Mar 24
TRUL: Schedule III Shift And Lower P E Multiple Will Drive Upside
Analysts have nudged their fair value price target for Trulieve Cannabis to CA$14.95, reflecting updated assumptions for slightly higher revenue growth, modestly improved profit margins, and a lower future P/E multiple in their models. Analyst Commentary While the latest fair value update suggests analysts see some improvement in Trulieve Cannabis' revenue and margin profile, there is still a clear undercurrent of caution in recent research across adjacent data and credit reporting names that can inform how you think about risk.Anlatı Güncellemesi • Mar 10
TRUL: Schedule III Shift And Higher P E Assumptions Will Drive Future Upside
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to about CA$14.95 from CA$14.69, reflecting updated assumptions around slower revenue growth, tighter profit margins and a much higher future P/E multiple that mirrors recent Street work, where price targets have been adjusted while views on long term earnings power and business mix continue to evolve. Analyst Commentary Street research around information services and data providers has recently highlighted how quickly sentiment can shift when investors question earnings durability, pricing power or the impact of new technology.Anlatı Güncellemesi • Feb 24
TRUL: Rescheduling To Schedule III Will Shape Future Upside Potential
Analysts have trimmed their price target on Trulieve Cannabis by a small amount to reflect a slightly lower fair value estimate of CA$14.69. This incorporates updated assumptions that include modestly adjusted revenue growth, profit margin outlook and future P/E expectations.Analiz Makalesi • Feb 12
Some Confidence Is Lacking In Trulieve Cannabis Corp. (CSE:TRUL) As Shares Slide 30%
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has softened a substantial 30% over the previous 30 days, handing...Anlatı Güncellemesi • Feb 09
TRUL: Rescheduling To Schedule III Will Support Higher Future Earnings Multiples
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to $19.53 from $19.06, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E levels. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which would apply to companies such as Trulieve Cannabis that operate in the sector (Marijuana Herald).Anlatı Güncellemesi • Jan 25
TRUL: Future Rescheduling And Tax Relief Prospects Will Shape Upside Potential
Analysts have trimmed their fair value estimate for Trulieve Cannabis by about $0.12 to roughly $14.78, reflecting updated assumptions around slightly higher revenue growth, a wider profit margin profile, and a lower future P/E multiple. Analyst Commentary Some bearish analysts are using the latest fair value trim as a reminder that execution and growth expectations for Trulieve Cannabis still carry meaningful risk, even with a higher revenue and margin outlook built into the model.Anlatı Güncellemesi • Jan 11
TRUL: Retail Expansion And Rescheduling Progress Will Support Higher Future Earnings Multiples
Analysts have made a small upward adjustment to their Trulieve Cannabis fair value estimate, reflecting only modest tweaks to long term profit margin and future P/E assumptions rather than a wholesale shift in their outlook. Analyst Commentary Recent Street research around comparable business services and data providers offers some useful clues for how analysts may be thinking about Trulieve Cannabis valuation and execution, even though the coverage is focused on different companies.Anlatı Güncellemesi • Dec 27
TRUL: Retail Expansion Into New States Will Drive Future Earnings Multiples
Analysts nudged their price target on Trulieve Cannabis slightly higher, by about $0.16, as they factor in stronger multi year revenue growth, improving profit margins, and a more reasonable future earnings multiple, while still maintaining a similar discount rate framework. Analyst Commentary Recent commentary around Trulieve Cannabis reflects a more constructive, yet still measured, stance as analysts incorporate updated assumptions for growth, profitability, and regulatory visibility into their valuation work.Analiz Makalesi • Dec 22
Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 55% But Its Business Is Yet to Catch Up
Trulieve Cannabis Corp. ( CSE:TRUL ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Dec 13
TRUL: Future Execution And Regulatory Shifts Will Shape Risk-Reward Balance
Analysts have lifted their price target on Trulieve Cannabis to approximately $14.90 from about $11.01, citing stronger expected revenue growth, improved profit margins, and a more reasonable future P/E multiple despite a slightly higher discount rate. Analyst Commentary Bearish analysts acknowledge Trulieve Cannabis's improved outlook but remain wary of execution and valuation risks in a still evolving regulatory and competitive landscape.Anlatı Güncellemesi • Nov 22
TRUL: Retail Expansion And New Markets Will Support Share Price Momentum
The analyst price target for Trulieve Cannabis has decreased slightly from $19.16 to $18.87. Analysts cite modest adjustments to profit margin expectations and valuation metrics as reasons for the change.Analiz Makalesi • Nov 08
Trulieve Cannabis Corp. (CSE:TRUL) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Shareholders might have noticed that Trulieve Cannabis Corp. ( CSE:TRUL ) filed its quarterly result this time last...Analiz Makalesi • Nov 07
Some Trulieve Cannabis Corp. (CSE:TRUL) Shareholders Look For Exit As Shares Take 29% Pounding
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has softened a substantial 29% over the previous 30 days, handing...Anlatı Güncellemesi • Nov 07
TRUL: Future Market Expansion Will Drive Share Price Momentum
Trulieve Cannabis’s analyst price target has been raised from $17.89 to $19.16. Analysts cite improved revenue growth projections and stable profit margins as key drivers for the upward revision.Analiz Makalesi • Oct 27
We Think Trulieve Cannabis (CSE:TRUL) Is Taking Some Risk With Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Aug 29
Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 97% But Its Business Is Yet to Catch Up
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 97% gain in the last month...Analiz Makalesi • Jul 11
Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 28%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 28% gain in the last month...Analiz Makalesi • Jun 12
Does Trulieve Cannabis (CSE:TRUL) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Yeni Anlatı • Mar 25
Adult-Use Cannabis Expansion In Florida And Pennsylvania Will Broaden Markets
Strategic retail expansion and new market entry in key states could significantly boost revenue and market share by tapping into adult-use markets.Analiz Makalesi • Jan 10
Here's Why Trulieve Cannabis (CSE:TRUL) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • Dec 05
More Unpleasant Surprises Could Be In Store For Trulieve Cannabis Corp.'s (CSE:TRUL) Shares After Tumbling 56%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have had a horrible month, losing 56% after a relatively good period...Analiz Makalesi • Sep 04
Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 47%?
Key Insights The projected fair value for Trulieve Cannabis is CA$24.05 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Jun 15
Trulieve Cannabis Corp.'s (CSE:TRUL) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Trulieve Cannabis Corp. ( CSE:TRUL ) shareholders won't be pleased to see that the share price has had a very rough...Analiz Makalesi • Jun 06
Trulieve Cannabis Corp.'s (CSE:TRUL) CEO Will Probably Struggle To See A Pay Rise This Year
Key Insights Trulieve Cannabis' Annual General Meeting to take place on 12th of June Salary of US$750.0k is part of CEO...Analiz Makalesi • May 01
Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 38%?
Key Insights The projected fair value for Trulieve Cannabis is CA$32.01 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Mar 31
Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 26%
Trulieve Cannabis Corp. ( CSE:TRUL ) shares have continued their recent momentum with a 26% gain in the last month...Analiz Makalesi • Feb 15
Is Trulieve Cannabis (CSE:TRUL) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Jan 16
There's Reason For Concern Over Trulieve Cannabis Corp.'s (CSE:TRUL) Massive 29% Price Jump
The Trulieve Cannabis Corp. ( CSE:TRUL ) share price has done very well over the last month, posting an excellent gain...Hissedar Getirileri
| TRUL | CA Pharmaceuticals | CA Pazar | |
|---|---|---|---|
| 7D | 16.9% | -2.0% | -1.1% |
| 1Y | 215.9% | -6.6% | 29.2% |
Getiri vs. Endüstri: TRUL geçen yıl % -6.6 oranında getiri sağlayan Canadian Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: TRUL geçen yıl % 29.2 oranında getiri sağlayan Canadian Piyasasını aştı.
Fiyat Oynaklığı
| TRUL volatility | |
|---|---|
| TRUL Average Weekly Movement | 15.1% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.7% |
İstikrarlı Hisse Senedi Fiyatı: TRUL hisse senedi fiyatı, son 3 ayda Canadian piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: TRUL 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala Canadian hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. bir kenevir perakendecisi olarak faaliyet göstermektedir. Şirket kenevir ürünleri yetiştirmekte, işlemekte ve üretmekte ve ürünlerini dispanserlerine ve eve teslimat yoluyla dağıtmaktadır. Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, Trekkers ve Roll One markaları altında çiçekler, yenilebilir ürünler, konsantreler ve aksesuarlar satmaktadır.
Trulieve Cannabis Corp. Temel Bilgiler Özeti
| TRUL temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | CA$3.10b |
| Kazançlar(TTM) | -CA$106.04m |
| Gelir(TTM) | CA$1.63b |
1.9x
P/S Oranı-29.3x
F/K OranıTRUL aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| TRUL gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.17b |
| Gelir Maliyeti | US$472.15m |
| Brüt Kâr | US$698.03m |
| Diğer Giderler | US$774.07m |
| Kazançlar | -US$76.04m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.40 |
| Brüt Marj | 59.65% |
| Net Kâr Marjı | -6.50% |
| Borç/Özkaynak Oranı | 25.3% |
TRUL uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/11 13:01 |
| Gün Sonu Hisse Fiyatı | 2026/06/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Trulieve Cannabis Corp. 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Matt Bottomley | Canaccord Genuity |